Holon, Israel

Avishay Denizel

This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Syqe Medical Ltd.. Active years: 2019-2024.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 37(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Avishay Denizel: Innovator in Inhaler Technology

Introduction

Avishay Denizel is a notable inventor based in Holon, Israel. He has made significant contributions to the field of inhaler technology, holding 2 patents that showcase his innovative approach to improving user experience and functionality in inhalation devices.

Latest Patents

One of his latest patents is for a replaceable flow tract for an inhaler. This invention provides a unique solution for delivering substances to users through an inhaler device. The design includes a housing that accommodates the flow tract and a construct containing source material for substance release. The replaceable flow tract features a conduit with multiple openings, including an elastic sealing member that ensures a secure fit against the construct when in use.

Career Highlights

Avishay Denizel is currently associated with Syqe Medical Ltd., a company known for its advancements in medical technology. His work at Syqe Medical has allowed him to focus on developing innovative solutions that enhance the effectiveness of inhalation devices.

Collaborations

He has collaborated with talented individuals such as Itay Kurgan and Abraham Meyer, contributing to a dynamic team that drives innovation in their field.

Conclusion

Avishay Denizel's contributions to inhaler technology reflect his commitment to improving healthcare solutions. His patents and work at Syqe Medical Ltd. highlight his role as a key innovator in this important area.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…